Edition:
India

Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

1.08USD
15 Feb 2019
Change (% chg)

$-0.04 (-3.57%)
Prev Close
$1.12
Open
$1.11
Day's High
$1.14
Day's Low
$1.08
Volume
17,192
Avg. Vol
42,988
52-wk High
$4.04
52-wk Low
$0.75

Chart for

About

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged... (more)

Overall

Beta: 2.10
Market Cap(Mil.): $70.63
Shares Outstanding(Mil.): 30.11
Dividend: --
Yield (%): --

Financials

  SPHS.OQ Industry Sector
P/E (TTM): -- 30.48 33.70
EPS (TTM): -0.26 -- --
ROI: -47.03 14.95 14.45
ROE: -97.97 16.27 15.96

SNB has sufficient tools to deal with more market volatility: Jordan

ZURICH The Swiss National Bank can deal with more market volatility in the financial markets with its current array of measures, Chairman Thomas Jordan said on Thursday.

24 Jan 2019

SNB has sufficient tools to deal with more market volatility - Jordan

ZURICH, Jan 24 The Swiss National Bank can deal with more market volatility in the financial markets with its current array of measures, Chairman Thomas Jordan said on Thursday.

24 Jan 2019

SNB still sees correction risk in Swiss real estate market

ZURICH, Sept 20 The Swiss National Bank (SNB) again warned that Swiss mortgage and real estate markets could tumble, pointing to continued increases in banks' mortgage lending and a rise in housing prices amidst growing vacancies as persistent imbalances.

20 Sep 2018

Earnings vs. Estimates